CDH2 and chronic myelogenous leukemia, BCR-ABL1 positive: Additionally, GC-4-mediated blocking of N-cadherin engagement between human CD34+ CML cells and stromal cells increased tumour cell sensitivity to imatinib, demonstrating a potential therapeutic strategy to overcome tyrosine kinase inhibitor resistance [131].